What is the 13F Pro Quality Score for CV?

13F Pro ranks CapsoVision, Inc (CV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CV's current score at https://13fpro.ai/company/CV (free sign-up required for the full ranking).

Where does 13F Pro source CV data?

All CapsoVision, Inc fundamentals and ownership data come directly from SEC EDGAR. CapsoVision, Inc files with the SEC under CIK 1378325. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CV in?

CapsoVision, Inc (CV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CV research updated on 13F Pro?

CV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CapsoVision, Inc(CV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1378325 CV stock profile & AI dashboard →

13F Pro Quality Score

20.8/100

Rank #2,772 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CV Scores 21/100

exact factor attribution · 2026-09-11

CV's composite is held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+0.8 pts

54th pct

Institutional flow

+0.0 pts

50th pct

Shareholder dilution

-1.2 pts

26th pct

Earnings growth

-2.2 pts

5th pct

Earnings quality

-3.5 pts

15th pct

Capital efficiency

-4.9 pts

1th pct

Profitability

-6.0 pts

10th pct

Free cash flow

-6.2 pts

9th pct

Scale

-6.2 pts

9th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CV Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CapsoVision, Inc (CV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CV at 20.8/100 on a 32-signal composite quality model, placing it at rank #2,772 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), CapsoVision, Inc reports quarterly revenue of $3.6M, net income of $-7.5M, free cash flow of $-8.4M. Top institutional holders of CV by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. CV trades on the Nasdaq exchange and files with the SEC under CIK 1378325. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CapsoVision, Inc directly from SEC EDGAR. CapsoVision, Inc's 13F Pro composite quality score has ranged between 21 and 25 since 2026, currently 20.8 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$3.6M

Net Income

Q2 2026

$-7.5M

Free Cash Flow

Q2 2026

$-8.4M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+15.3% YoY

$13.6MFY 2025

FY23 —FY24 $11.8MFY25 $13.6M

Net Income

-27.2% YoY

$-25.3MFY 2025

FY23 —FY24 $-19.9MFY25 $-25.3M

Operating Income

-28.1% YoY

$-25.5MFY 2025

FY23 —FY24 $-19.9MFY25 $-25.5M

EPS (Diluted)

-98.7% YoY

$-1.03FY 2025

FY23 —FY24 $-0.52FY25 $-1.03

Total Assets

+8.1% YoY

$18.2MFY 2025

FY23 —FY24 $16.8MFY25 $18.2M

Op. Cash Flow

-13.8% YoY

$-22.9MFY 2025

FY23 —FY24 $-20.1MFY25 $-22.9M

Free Cash Flow

-13.4% YoY

$-23.0MFY 2025

FY23 —FY24 $-20.2MFY25 $-23.0M

Metric	FY 2025	FY 2024	FY 2023
Revenue	$13.6M +15.3%	$11.8M	—
Net Income	$-25.3M -27.2%	$-19.9M	—
Operating Income	$-25.5M -28.1%	$-19.9M	—
EPS (Diluted)	$-1.03 -98.7%	$-0.52	—
Total Assets	$18.2M +8.1%	$16.8M	—
Operating Cash Flow	$-22.9M -13.8%	$-20.1M	—
Free Cash Flow	$-23.0M -13.4%	$-20.2M	—

Get alerted when CV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CapsoVision, Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CV

BlackRock, Inc.
$14.4M1,896,088 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.0M1,058,468 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.4M578,482 sh
STATE STREET CORP
$3.1M410,241 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.8M240,425 sh
NORTHERN TRUST CORP
$1.7M220,095 sh
VANGUARD FIDUCIARY TRUST CO
$785.5K103,630 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$601.5K79,360 sh
Bank of New York Mellon Corp
$568.7K75,021 sh
Nuveen, LLC
$348.8K46,011 sh

Fund	Value	Shares
BlackRock, Inc.	$14.4M	1,896,088
VANGUARD CAPITAL MANAGEMENT LLC	$8.0M	1,058,468
GEODE CAPITAL MANAGEMENT, LLC	$4.4M	578,482
STATE STREET CORP	$3.1M	410,241
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.8M	240,425
NORTHERN TRUST CORP	$1.7M	220,095
VANGUARD FIDUCIARY TRUST CO	$785.5K	103,630
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$601.5K	79,360
Bank of New York Mellon Corp	$568.7K	75,021
Nuveen, LLC	$348.8K	46,011

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CV on your watchlist

Track score changes the day CapsoVision, Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CV a good stock to buy?

13F Pro's AI-powered analysis of CapsoVision, Inc (CV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CV are available on the CV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CV is classified as a small company.

Which hedge funds own CV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CapsoVision, Inc's investment landscape.